Abstract Early studies regarding the function of FceRI in dendritic cells (DCs) and monocytes have focused on its role in mediating inflammatory signaling and enhancing T cell immunity. It has been the case in part because FceRI is the major receptor that mediates allergic inflammatory signaling in mast cells and basophils and because DCs and monocytes are antigen presenting cells capable of activating naïve and/or effector T cells. These studies have led to the general belief that FceRI-mediated DC signaling and antigen presentation promote development and activation of Th2 cells and contribute to allergic inflammatory diseases. However, this belief has long suffered from a lack of evidence. Recently, studies have emerged that provide evidence supporting an opposing role: that FceRI on DCs instead promotes immune homeostasis and regulation. In this review, we will update the current status of our understanding of FceRI biology and function, with a specific focus on DCs and monocytes.
Introduction
FceRI is constitutively expressed by mast cells and basophils, and captures IgE in its monomeric form owing to its remarkably high affinity to IgE (K d = 10 -10 M). When IgE/FceRI complexes on these cells are engaged and crosslinked by allergens, a signaling cascade is initiated that results in extracellular release of various inflammatory mediators [1, 2] . One example of such mediators is histamine, which dilates blood vessels and makes their walls abnormally permeable, creating hives. FceRI is also expressed in dendritic cells (DCs), both conventional and plasmacytoid DCs, and monocytes in humans. DCs and monocytes are both antigen-presenting cells that endocytose antigens, and process and present them to antigenspecific T cells via antigen presenting molecules including the major histocompatibility complex (MHC) [3, 4] . The antigen presenting activity of DCs plays an important role in the development of antigen-specific immunity by activating naïve T cells and assisting in T helper cell skewing [5, 6] . DC antigen presenting activity also plays an essential role in establishing and maintaining tolerance either by deleting self-reactive T cells or by generating the immune suppressive regulatory T cells [7] . DCs and monocytes also act as innate immune cells. They produce various cytokines and chemokines in response to danger signals such as microbes and tissue damage-associated molecules [8] . In particular, plasmacytoid DCs produce copious amounts of type 1 IFN in response to viral infection signal. Sensing of these signals is mediated by a variety of receptors expressed on the surface and endosomal compartment of the cells [9, 10] .
Although the expression of FceRI in DCs and monocytes has been known for more than two decades, its functional role is not clearly understood-in part, because studies have suffered from a lack of essential reagents. Rodents are the vertebrate species most commonly used in research laboratories because of their availability, size, low cost, ease of handling and fast reproduction rate. Rodents constitutively express high levels of FceRI in mast cells and basophils in a fashion similar to humans, and thus have served as excellent animal models and cellular sources for studying the role of FceRI on these cell types. However, rodents do not express FceRI in DCs and monocytes under homeostatic condition while humans do. Therefore, studies in this field have been limited to in vitro experiments using DCs and monocytes obtained from human donors. Although monocytes are available more readily than any other primary human cells, only a small fraction of the cells express FceRI, and the level of expression is considerably reduced upon culture. DCs are not only scarce in most tissues, but are comprised of many subsets whose markers and functions are not completely understood. All these drawbacks have markedly slowed down the progress in the field.
In recent years, however, substantial advancement has been made in the characterization of human DC subsets. Subset-specific markers have been identified, which have allowed for examination of DCs in situ by microscopy in a variety of human tissues. Identification of markers has also helped with isolation and further characterization of DCs by flow cytometry and various biochemical assays. Beyond improvements in DC identification, advancements have been also made in culturing human DCs. DCs can be derived from blood monocytes or CD34
? blood precursors, and some of these cultured DCs express FceRI in a stable manner. Finally, the advent of genetic engineering technology has led to the creation of mouse strains that express human FceRI in DCs and/or monocytes in a pattern that resembles human. These mouse strains made it possible to examine the role of human FceRI in vivo, and furthermore to examine the role of DCs and monocytes in FceRI function. In this review, we will describe these advancements in detail and summarize the current understanding of FceRI biology in DCs and monocytes. Occasionally, it will be compared with FceRI biology in mast cells and basophils, and highlighted for its distinctiveness.
FceRI expression specificity and heterogeneity in DCs and monocytes
FceRI expression in DCs was first observed in the skin epidermis, where a distinct subset of DCs named Langerhans cells was found [11, 12] . Immunohistochemical and flow cytometry studies showed that epidermal skin cells labeled by the anti-CD1a antibody, a specific marker of Langerhans cells, were also labeled by an anti-FceRIa antibody as well as IgE [11, 12] . Immunogold labeling electron microscopy study also showed that epidermal skin cells that contained Birbeck granules in the cytosol, the specific characteristics of Langerhans cells, were decorated by anti-FceRI antibody-conjugated gold particles on their surface [12] FceRI expression in monocytes was first characterized in atopic blood donors and later in healthy individuals [29, 30] . FceRI expression appears to be limited only to a small subset of monocytes characterized by the expression of CD2 [31] . CD2
? monocytes are CD16 -and occupy less than 5 % of the total monocytes in peripheral blood.
Studies have shown that CD2
? monocytes rapidly obtain DC-like features in culture, including the expression of CD83 and the ability to activate allo-reactive T cells [32, 33] . Therefore, it is conceivable that CD2
? monocytes differentiate to DCs in the peripheral tissues, thus contributing to the pool of peripheral DCs that express FceRI. Considering that monocytes also differentiate into macrophages, but macrophages do not express FceRI [48] , implicating FceRIa may be modified by distinct glycan moieties depending on cell type of its expression, similarly to FccRIIIa [49] .
The c-subunit of FceRI is a transmembrane protein that acts as a common adaptor molecule for various Fc receptors such as FccRI (CD64), and FccRIIIA (CD16A) [50, 51] . It associates as a homodimer formed via a disulfide bond linked between N-terminal cysteine amino acids. The N-terminus also bears an immunoreceptor tyrosine-based activation motif (ITAM), which is phosphorylated upon FceRI engagement and plays an essential role in transmitting activation signals in mast cells and basophils [52] . A similar role is believed to be played in DCs and monocytes.
It is worth of mentioning that in mast cells and basophils, some, if not all, FceRI molecules associate with an additional protein subunit, FceRIb. The FceRIb subunit is a membrane protein composed of four transmembrane and two cytoplasmic domains, one of which contains an ITAM. This additional ITAM is not required for, but markedly amplifies, signal transduction triggered by FceRI engagement [53] . Expression of FceRIb also enhances FceRIa transport to the plasma membranes [54] . FceRIb expression has been reported in Langerhans cells; they demonstrated the presence of FceRIb mRNA by RT-PCR after enrichment of Langerhans cells from epidermal cell suspension [12] . However, a later study that used highly purified Langerhans cells ([98 %) showed the lack of FceRIb in these cells [55] . Thus, it is possible that early samples may have contained contaminating mast cells from the Langerhans cell purification process. Additional DC subsets including BDCA1
? DCs, plasmacytoid DCs, and monocytes have been examined for the expression of FceRIb, but none of these cells were found to express it. Thus, DCs and monocytes, distinct from mast cells and basophils, appear to express FceRI only in its trimeric form.
FceRI intracellular trafficking in DCs and monocytes

Secretory trafficking
Upon synthesis, the FceRI a-subunit is inserted to the ER membranes and glycosylated at its luminal sites. This process is dependent on cotranslational assembly with the c-subunits [56] . The c-subunit also facilitates the ER exit of FceRIa by masking an ER retention/retrieval signal present in the a-subunit cytoplasmic tail [57] . Consequently, the level of c-subunit expressed in cells makes a substantial impact on the level of FceRI found on the plasma membrane. For example, Langerhans cells hardly express FceRIc while expressing substantial levels of FceRIa [58] . Because of their FceRIc deficiency, FceRIa in these cells fails to move to the plasma membranes and instead accumulates in the ER. Similarly, DCs derived from monocytes in vitro also lack FceRIc, and thus express little or no FceRI at the plasma membrane [36] . However, DCs derived from monocytes of patients with atopic dermatitis express detectable levels of FceRI on their surface. An attractive explanation for these differences lies in the finding that DCs derived from atopic donors expressed FceRIc, which would have promoted FceRIa exit from ER and led to the transport of trimeric receptor to the plasma membranes [36] . BDCA1 ? DCs isolated from blood express both FceRIa and FceRIc, and the level of their surface FceRI expression is fairly high. In these cells, FceRIa is not detected in the ER or in the Golgi, nor is the immature species of FceRIa Novel function of FceRI 2351 detected, defined as FceRIa that still contains its high mannose carbohydrates attached in ER [48] . This high mannose glycans are later modified to a more complex form of glycans in the Golgi-a process referred to as FceRIa maturation [56] . Thus, the absence of immature FceRIa species together with the absence of FceRI in ER and Golgi strongly suggest that FceRI efficiently matures and traffics to the plasma membranes in BDCA1 ? DCs. Considering that immature FceRIa is readily detected in human basophils, both by microscopy and western blot analysis [48, 59] , it is conceivable that the efficiency of secretory trafficking of FceRI might be higher in DCs than basophils. Unlike basophils, however, mast cell FceRI is not detected in the ER, but instead found in the Golgi [60] . It will be interesting to directly determine and compare the efficiency of FceRI secretory trafficking between these cell types, as it may be relevant to the unique functional roles played by FceRI in these cells.
Endocytic trafficking
Treating blood DCs with anti-FceRI antibodies or anti-NP IgE/NP-BSA complexes, which would synchronously crosslink FceRI molecules on the surface of the cells, results in approximately 90 % of FceRI disappearing from plasma membrane within 10 min [61] . Microscopy studies revealed that crosslinked surface FceRI enters the cells and reaches the lysosomes where FceRI-bound IgE is degraded over time [61] . This finding indicates that FceRI in DCs is rapidly endocytosed and transported to the lysosomes upon crosslinking. In fact, similar crosslinking-dependent endocytosis of FceRI has been also described in mast cells, in which crosslinking initiates ubiquitination of FceRI b-and c-subunits, which leads FceRI to clathrin coated pits where the physical process of endocytosis occurs [62] .
Interestingly, a recent study has shown that FceRI in DCs and monocytes is endocytosed and transported to the lysosomes in a constitutive manner. Microscopic study of human blood DCs and monocytes revealed that a large fraction of FceRI in these cells resides in the lysosomes under homeostatic condition and that these cells contain appreciable amounts of IgE inside the cells [48] . While there could presumably be a physiologic FceRI-crosslinker in the blood, monomeric IgE added to DCs in culture was also spontaneously internalized [48] . Thus, it is likely that DCs constantly internalize FceRI in a crosslinking-independent manner, and IgE bound to the FceRI is also internalized during this process. Importantly, no such constitutive internalization of IgE was observed in mast cells or basophils [48] . This finding strongly suggests that DCs and monocytes operate a unique mechanism by which FceRI is constitutively endocytosed and sorted to the lysosomes.
Endocytosis of FceRI bound by IgE draws a particular attention because previous literatures have extensively described the role of IgE in inhibiting FceRI endocytosis. Repetitive injection of IgE into mice results in a substantial increase in the surface expression of FceRI in mast cells and basophils [63, 64] . Conversely, mast cells and basophils from IgE-deficient mice have significantly reduced FceRI compared to those from wild type mice [63, 64] . In vitro, addition of IgE to cultures of FceRI-expressing cells also increases FceRI surface levels [63] [64] [65] [66] . Mechanism studies have shown that this increase in plasma membrane expression of FceRI upon IgE binding is not by the increase in FceRI synthesis but by the decrease in FceRI endocytosis [65, 67] , leading the conclusion that IgE binding stabilizes FceRI at the plasma membrane by inhibiting its internalization and degradation. However, these previous studies were performed using human basophils [66, 67] , bone marrow-derived mouse mast cells [64] and hFceRI-transfected cell lines of either hematopoietic or non-hematopoietic origin expressing either trimeric or tetrameric FceRI [65] , but not DCs or monocytes isolated from human tissues. In fact, a similar study performed using human Langerhans cells has shown that FceRI surface levels decrease during ex vivo culture, and this decrease is not prevented by addition of IgE [58] . A recent study using blood DCs in children has shown no correlation between FceRI in conventional DCs and serum IgE unless serum IgE levels reached certain threshold [68] . More recently, FceRI expression in blood DCs and basophils in adults were examined in reference to a broad range of serum IgE. While FceRI in basophils sharply increased in correlation with serum IgE levels, FceRI in DCs remained fairly flat [48] , suggesting that DCs control FceRI surface levels distinctly from basophils in a manner independent of extracellular IgE.
FceRI function in DCs and monocytes
Signaling: immune stimulatory or suppressive FceRI-mediated signaling has been extensively studied in mast cells. Cross-linking of IgE bound to FceRI with multivalent antigen triggers a series of biochemical events that culminate in multiple mast cell effector functions [69] [70] [71] . Signaling is initiated through the phosphorylation of ITAMs in the cytoplasmic tails of the FceRIb and FceRIc subunits by the Src protein tyrosine kinases such as Lyn, which are recruited upon clustering of FceRI. The phosphorylated ITAMs then recruit the kinase Syk, which mediates activation of the adaptor molecules LAT and SLP76, resulting in calcium mobilization. Ultimately, FceRI aggregation results in initiation of the allergic inflammatory process by eliciting mast cell degranulation with a rapid release of preformed vasoactive amines like histamine and the de novo synthesis of proinflammatory cytokines like TNF-a and IL-6.
Comparatively little is known of the signaling events following FceRI engagement in DCs and monocytes. Particularly, early signaling events have been poorly characterized; no studies have directly shown that the ITAMs of the FceRIc subunit are phosphorylated following FceRI crosslinking in DCs or monocytes. In mast cells and basophils, FceRI proximal signaling is largely dependent on the FceRIb subunit, which markedly reduces the extent of FceRI crosslinking required for initiation of signaling [53] . Since monocytes and DCs lack FceRIb, FceRI signaling in these cells may require heavy crosslinking of FceRI, which may be hard to achieve due to its constitutively endocytosis. Nevertheless, FceRI crosslinking has been shown to induce protein tyrosine phosphorylation and calcium mobilization in Langerhans cells [55] . It also induces activation of NF-jB in Langerhans cells, monocytes, and monocyte-derived DCs [72] . The NF-jB activation is preceded by serine phosphorylation of IjB-a. The activated NF-jB complexes contain p50 and p65 subunits, and leads to the synthesis and release of TNF-a and MCP-1 (CCL-2) from monocytes and monocyte-derived DCs [72] .
Consistent with the role of NF-jB in increasing transcription of proinflammatory mediators, FceRI crosslinking in monocytes and DCs, results in the production of TNF-a and IL-6 [73] [74] [75] [76] . Blood conventional DCs also produce CCL-28, a chemokine that recruits T and B cells and eosinophils [77] . Inflammatory DCs cultured from monocytes were shown to produce IL-12 and IL-18, which are both potent proinflammatory and IFN-c producing cytokines [78] . These studies suggest that FceRI signaling in DCs and monocytes may promote inflammation by upregulating the production of cytokines and chemokines that activate and recruit a variety of types of inflammatory cells.
However, studies also suggest an anti-inflammatory and immune suppressive role of FceRI signaling. FceRI crosslinking in monocytes and DCs has been shown to induce high amounts of the anti-inflammatory cytokine IL-10, which subsequently acts in an autocrine fashion and negatively regulates production of TNF-a in these cells [74] [75] [76] 79] . Additionally, a high-throughput analysis has been performed to identify genes regulated by FceRI signaling in a non-biased manner. This study has revealed that at relatively later time points following FceRI-crosslinking, monocytes upregulate the expression of indoleamine 2,3-dioxygenase (IDO), the rate-limiting enzyme in the catabolism of tryptophan [80] . IDO production from macrophages and DCs, and consequent depletion of tryptophan, have been shown to inhibit T cell proliferation in part by activating a cellular stress response or by inducing activation and regulatory function of functionally quiescent regulatory T cells [81, 82] . Indeed, FceRI-crosslinked monocytes markedly suppressed proliferation of T cells in vitro and this suppression was reverted when the culture was supplemented with tryptophan or an IDO inhibitor [80] .
Additional data further support the role of FceRI signaling in immune-suppression. Toll-like Receptor (TLR) 7 and TLR 9 mediate activation of PDCs during viral infection resulting in the production of type 1 IFNs such as IFN-a and -b. Several studies have shown that FceRI aggregation significantly reduced the production of IFN-a and IFN-b by plasmacytoid DCs stimulated with CpG-A (a ligand of TLR9), influenza virus, or gardiquimod (a TLR 7 agonist) [76, 83, 84] . This down-regulation in IFN responses was accompanied by a concomitant reduction in the transcription of TLR 7 or TLR 9 [76, 84] . More recently, it was shown that FceRI crosslinking in monocytederived DCs reduces production of CCL-2 following stimulation with lipopolysaccharide, a ligand of TLR 4 [85] , suggesting that FceRI signaling interferes with TLR signaling not only in plasmacytoid DCs but also monocytederived DCs and possibly conventional DCs.
Antigen presentation: immunogenic or tolerogenic
Dendritic cells and monocytes are professional antigen presenting cells in humans. Therefore, the identification of FceRI expression in these cells naturally prompted the question of whether this receptor might facilitate presentation of IgE-bound antigens. Studies using multivalent antigens that bind and crosslink IgE/FceRI complexes have shown that these antigens were rapidly internalized by DCs and monocytes, processed by lysosomal proteases, loaded onto MHC II, and presented to antigen-specific CD4
? T cells, resulting in their proliferation [41, 61] . IgE loading was crucial to efficient antigen presentation because antigens added to cells in the absence of IgE were presented at a 100 to 1000-fold lower efficiency [41] . These findings suggest that FceRI facilitates presentation of IgE-bound antigens, such as allergens, to T cells-implicating its contribution to T cell-mediated inflammation in allergic diseases. More recently, plasmacytoid DCs loaded with Bet v1 allergen-IgE immune complexes were shown to induce activation of autologous naïve CD4 T cells producing higher amounts of IL-4 and lower levels of IFN-c than T cells cocultured with untreated plasmacytoid DCs [27] . A similar response has been also observed with naïve T cells cocultured with blood BDCA1
? DCs loaded with Der p1 allergen-IgE immune complexes [86] . These studies suggest that FceRI in DCs not only enhances activation of effector CD4 T cells but also mediates priming of Th2 cells.
Novel function of FceRI 2353
Recently, the role of FceRI in antigen presentation by DCs was further examined in vivo using transgenic mice [85, 87] . This strain expresses the human FceRIa under the control of the DC-restricted, constitutively active CD11c promoter. The human FceRIa expressed in DCs forms a complex with mouse FceRIc, transports to the plasma membranes, and binds circulating murine IgE albeit at a reduced affinity compared to human IgE. Two independent groups used these mice and examined whether DCs of this mouse present IgE-bound antigens better than DCs of wild type mouse, and if so, whether the antigen presentation results in Th2 cell priming [85] . While both studies concluded that FceRI greatly enhances DC presentation of IgE-bound antigens in vivo, they reached contradictory conclusions regarding Th2 cell priming; one study found improved Th2 cell generation [87] , but the other found no evidence of any improvement [85] . The reason behind this contradiction is not completely clear, but additional studies remain to be seen to clearly answer this long-standing question.
Another recent study examined the role of FceRI in DC antigen presentation using a unique hFceRIa-Tg mouse strain in a distinct experimental setting [88] . This study used mice that express hFceRIa under the control of human FceRIa promoter [89] . Accordingly, this mouse expresses hFceRIa in cell types where it is also expressed in humans, including mast cells, basophils, monocytes, and DCs, both conventional and plasmacytoid DCs. In this study, the mice were injected with a recombinant protein consisting of the human IgE Fc domain covalently linked to a specific peptide antigen, and examined for the presentation of the antigen to antigen-specific CD4
? T cells that had been adoptively transferred into the mice. Thus, this study examined the role of FceRI in mediating presentation of IgEbound monovalent antigen. The antigen was effectively presented by DCs to naïve T cells, resulting in T cell proliferation. However, the proliferation was transient and was followed by systemic deletion of the antigen-specific T cells from the mice. Furthermore, the mice became resistant to developing T cell immune responses against the antigen at later challenges. These findings suggest that FceRI facilitates DC presentation of IgE-bound antigens and that this presentation results in antigen-specific T cell tolerance as long as the IgE-bound antigens do not crosslink FceRI. Although such occasion remains to be identified in physiologic conditions, it may pertain to the production of natural IgE following tissue damage and its potential role in immune regulation. For example, helminth infection causes massive damage in the intestines and lungs, and is followed by production of high amounts of IgE antibodies, which are not specific for parasites but are polyclonal in nature [90, 91] . In addition, surgery and burns, both involving potentially severe tissue damage, are also accompanied by the production of considerable amounts of polyclonal IgE [92, 93] . Although the specificity of these IgE molecules remains to be determined, they are believed to be natural IgE, which is of low affinity and poly-specific against various self-antigens including phosphatidylcholine [94] . This natural IgE may promote DC recognition of self antigens released during tissue damage via FceRI-but this recognition is not likely to cause FceRI crosslinking because the likelihood of that an antigen-specific IgE molecule to be adjacent to the same antigen-specific IgE molecule is extremely low. In addition, IgE bound to FceRI will be rapidly internalized by DCs via constitutive FceRI endocytic trafficking, which will further minimize the likelihood of FceRI crosslinking. Consequently, the IgE-bound self-antigens would be internalized in the absence of FceRI crosslinking, subsequently presented to self-reactive T cells, which in turn would be deleted. Thus, IgE generated following tissue damage may play an important role in preventing autoimmunity from developing against self-antigens released during the damage by focusing the antigens to FceRI-expressing DCs, which induces deletional T cell tolerance against those antigens. In this context, FceRI in DCs would contribute to immune tolerance to selfantigens.
IgE clearance
IgE has the shortest serum half-life (approximately 2 days) among five immunoglobulin isotypes [95, 96] . In an interesting mathematical study of immunoglobulin metabolism, it was found that IgE differs from other immunoglobulins in that it undergoes substantial catabolism at extravascular sites [96] . The study proposed that the extravascular catabolism is part of a unique mechanism specific for IgE, which is related to unique interactions of IgE with cells expressing FceRI in the peripheral tissues. This interaction was considered to exert two potential effects on overall IgE survival; on one hand, it may result in sequestration and persistence of IgE molecules in local tissue sites. On the other hand, it may be followed by subsequent catabolism of IgE by the cells. Interestingly, they concluded that IgE catabolism after interaction with cells is a quantitatively more significant phenomenon than IgE sequestration.
Nevertheless, the role of FceRI-expressing cells in IgE catabolism has been difficult to prove experimentally. IgE bound to FceRI on mast cells persists as long as the cells are alive, which suggests that IgE bound to mast cells is stabilized rather than catabolized. Furthermore, mast celldeficient mice were found to clear IgE at a similar rate to wild type mice [97] . FceRI-deficient mice also cleared IgE similarly to wild type mice [98] . These findings have provided strong evidences supporting the hypothesis that FceRI-expressing cells do not contribute to IgE catabolism. However, humans differ from mice; in this case, in that human also express FceRI in monocytes and DCs. The role of these cells in IgE catabolism has not been examined until recently.
The recent finding that FceRI is constitutively endocytosed and transported to the lysosomes in human monocytes and DCs invited the question of whether IgE bound to FceRI in these cells would be also endocytosed and transported to the lysosomes, and possibly degraded by lysosomal proteases. Indeed, IgE bound to DCs but not basophils were rapidly endocytosed, transported to the lysosomes, and degraded [48] . To take it a step further, this study was extended to determine the role of monocytes and DCs in IgE catabolism in vivo [48] . The aforementioned hFceRIa-Tg mice that express human FceRIa under the human promoter were used in this study because these mice recapitulated not only the cell-type specific expression of FceRI but also the unique cell type-specific intracellular trafficking of the receptor; human FceRI was localized in endolysosomes in transgenic murine DCs and monocytes while it was localized in the plasma membranes in mast cells and basophils [48] . Human IgE injected to these mice was internalized by DCs and monocytes but not by mast cells and basophils. Furthermore, the transgenic mice cleared IgE at a much faster rate than non-transgenic control mice, and the rate of clearance correlated with the prevalence of monocytes and DCs. This study reveals that FceRI-mediated constitutive internalization of IgE by DCs and monocytes promotes serum IgE clearance, implicating its role in IgE homeostasis.
Association with diseases of FceRI-expressing DCs and monocytes
Atopic dermatitis
Atopic dermatitis, or eczema, is an inflammatory skin disease characterized by red and itchy dry rashes on the skin. The lesions are infiltrated by inflammatory cells and accompanied by keratinocyte metaplasia, and are often associated with high levels of total IgE and allergenspecific IgE. Blood monocytes from atopic dermatitis patients express significantly higher levels of FceRI than those from healthy individuals, implicating them in this disease. Crosslinking of FceRI in monocytes promotes differentiation of the monocytes to histamine receptor 1 (H1R)-expressing macrophages with high proinflammatory properties and increased histamine biosynthesis in vitro [99] . In agreement with these in vitro findings, H1R-expressing CD68
? macrophages were also found in high amounts in the dermal compartment of AD skin lesions. Considering that histamine is one of the most important mediators of allergic inflammatory reactions, FceRI signaling in monocytes may contribute to the generation of macrophages that initiate the inflammatory activities of histamines, aggravating skin inflammation in atopic dermatitis.
In addition to macrophages, the skin lesions of atopic dermatitis are infiltrated by a large numbers of DCs; namely, IDECs (inflammatory dendritic epidermal cells), which express distinctively high levels of FceRI on their surface [100] . Culturing monocytes with IL-4 and GM-CSF under reducing conditions generates DCs with similar phenotypes to IDEC, including high levels of FceRI [37] . These IDEC-like DCs produce inflammatory cytokines and chemokines including IL-12, and IL-18 upon FceRI crosslinking, which are enriched in lesion of atopic skin [78] . This finding suggests that FceRI signaling in IDEC may be a significant contributor to the skin inflammation in this disease.
Asthma
Asthma is a chronic inflammatory lung disease characterized by airway hyper-reactivity and excessive mucus production. Similar to atopic dermatitis, a major fraction of asthma is associated with high levels of total IgE and allergen-specific IgE in serum. It is also associated with both an increased expression of FceRI in DCs and monocytes and an infiltration of airways with FceRI-expressing DCs [13] . This infiltration by FceRI-expressing DCs is associated with a specific subset of asthma characterized by a Th2 immune profile, namely Th2 high asthma [28, 101] . This subset of asthma is also accompanied by a more severe form of eosinophilia and subepithelial fibrosis compared to Th2 low asthma [101] . Thus, FceRI signaling in DCs may be a contributing factor to Th2 inflammation and associated asthma pathologies.
The role of FceRI-expressing DCs in Th2 asthma pathologies has been also implicated in studies that used wild type mice as the animal models. While wild type mice do not express FceRI in DCs at steady state, mouse lung DCs do express FceRI following infection by the mouse paramyxovirus Sendai virus [102] . This virus induces acute Th1 antiviral immune responses but also triggers a later switch to persistent Th2 inflammation, mucous cell metaplasia, and airway hyper-reactivity, reminiscent of asthma associated with respiratory viral infection. As no previous studies have shown FceRI expression in mouse DCs, this study thoroughly tested FceRI expression on the DCs using multiple methods including flow cytometry, western blot analysis, and RT-PCR. These methods consistently pointed to the induction of FceRI expression in lung DCs following Novel function of FceRI 2355 the viral infection. This study further showed that crosslinking FceRIa on lung DCs of the mice resulted in the production of the T cell chemoattractant CCL-28. Furthermore, FceRIa-deficient mice had decreased CCL-28 and decreased recruitment of IL-13 producing CD4 T cells to the lung after viral infection. However, these decreases were reverted by transfer of DCs from wild type but not from FceRI-deficient mice. Thus, this study suggests that FceRI expressed in DCs contributes to allergic inflammation in the lung by recruiting Th2 cells that promote mucous cell metaplasia by mediating production of CCL-28.
In addition to mice infected with Sendai virus, mice intranasally challenged with house dust mite have been shown to express FceRI in a distinct subset of DCs namely inflammatory DCs [103] . However, this finding was solely dependent on detection of FceRI by flow cytometry using an anti-FceRI monoclonal antibody, MAR-1. Although the MAR-1 antibody binds mouse FceRI and has been frequently used to identify basophils and mast cells in mice, the degree of its specificity has not been extensively characterized. In fact, others and we have found that MAR-1 binds a subset of monocytes in FceRIa-deficient mice under inflammatory conditions. Additionally, no functional role has been reported in association with FceRI expressed by these inflammatory mouse DCs. Thus, further studies are required to verify FceRI expression by these mouse inflammatory DCs as well as its functional significance.
The role of FceRI expressed in DCs in asthma has been also examined using the CD11c-hFceRIa-Tg mice that express hFceRIa under control of the DC-specific CD11c promoter. One study showed that these mice produced a greater amount of IL-4 in the airways and developed a more severe form of lung eosinophilia compared to wild type mice, and that both phenotypes were completely dependent on IgE [87] . This finding suggests that FceRI on DCs promotes asthma. However, another study showed that these mice develop a comparable level of airway inflammation to wild type mice indicated by similar amounts of TNF-a, IL-6, IL-13, IL-5 produced in the airways and a similar degree of eosinophil recruitment [85] . In addition, the mice failed to develop airway hyper-reactivity while wild type mice did [85] . These findings suggest that FceRI on DCs may instead play a regulatory role in asthma. The apparent contradiction between these studies is not clearly explainable. It may be attributed to different microbiota in animals due to different housing facilities. Alternatively, it may be attributed to different asthma models used. The former employed an acute asthma model largely independent of mast cells while the latter adopted a chronic asthma model that significantly depends on mast cells. In fact, the latter study has shown that a smaller number of mast cells are recruited to the airways in the CD11c-hFceRIa-Tg mice than wild type mice. Similar observation was made in a mast cell-dependent food allergy model [85] . Based on these results, perhaps FceRI on DCs may specifically regulate mast cell-associated allergic inflammation.
Concluding remark
In this review, we have summarized the current knowledge of FceRI biology on human DCs and monocytes. FceRI is homogeneously and constitutively expressed by the major human DC subset, the BDCA1
? conventional DCs, and also by BDCA2
? plasmacytoid DCs throughout various tissue sites. FceRI is also constitutively expressed in Langerhans cells, the distinct skin DC subset. Exceptions are the BDCA3
? conventional DCs that lack FceRI. Unlike DCs, monocytes express FceRI in a heterogeneous and more regulated manner. In both monocytes and DCs, FceRI is effectively transported to the plasma membranes but also effectively endocytosed. This endocytosis is not inhibited by IgE binding, thereby resulting in FceRI-bound IgE entering the cells, reaching the lysosomes, and becoming subject to degradation (Fig. 1a) . This distinct FceRI trafficking may render monocytes and DCs an IgE cleaner as opposed to an IgE effector. When antigens come into the picture, FceRI endocytosis reinforces the ability of DCs to internalize, process, and present antigens by focusing these activities toward antigens bound to IgE. The consequences of this antigen presentation may differ depending on whether or not FceRI was crosslinked during engagement with antigens; in the absence of crosslinking, the antigen presentation results in deletional T cell tolerance whereas in the presence of crosslinking, it may result in development of effector T cells (Fig. 1b, c) . Besides antigen presentation, FceRI mediates intracellular signaling upon crosslinking (Fig. 1c) . This signaling could either promote or inhibit immune stimulation depending on environmental factors including tissue sites, neighboring cells, and cytokines. Based on its ability to promote antigen presentation as well as to transmit signaling, FceRI in DCs and monocytes has been suggested to contribute to allergic diseases by enhancing T cell immunity and inflammation. However, recent studies using murine models raise the possibility that it may instead function as the regulator of allergic inflammation.
There is no question that additional studies are required to clarify the functional role of FceRI in DCs and monocytes. The recently emerged animal models are expected to continue serving useful reagents to the field. However, caution is urged, as they express the chimeric receptor composed of the human FceRIa and the mouse FceRIc, which do not exist in either humans or mice. In addition, mouse DCs and monocytes may not behave the same as human counterparts. Therefore, studies using human cells will need to be accompanied with mouse models, and studies using mice will need to be thoroughly assessed for their validity and relevance to human physiology or disease. Alternatively, one may utilize a humanized mouse strain in which their immune cells were derived from human hematopoietic stem cells. In fact, a human PBMCengrafted murine model of gut allergic inflammation has been recently developed [104] . This model depends on human FceRI-expressing cells; thus, it could serve a tool to examine the role of FceRI-expressing DCs or monocytes in gut allergic inflammation. It is clear that the field is moving fast forward, and a major progress is to be seen in the near future. Fig. 1 Role of FceRI in DCs and monocytes. a IgE clearance. FceRI on DCs and monocytes captures extracellular IgE and takes it to the lysosome resulting in the intracellular degradation [48] . b T cell tolerance. FceRI takes IgE-bound antigen to the lysosomes resulting in the generation of antigenic peptides. These peptides are loaded onto MHCII, transported to cell surface, and presented to antigenspecific CD4
? T cells. This function is not dependent on FceRI crosslinking; non-crosslinking antigens as well as crosslinking antigens are internalized and presented to CD4
? T cells [61, 88] . When antigen presentation is made in the absence of FceRI crosslinking, the antigen-recognizing T cells undergo apoptosis resulting in development of T cell tolerance [88] . c Pro-or antiinflammation. FceRI transmits intracellular signaling upon crosslinking that results in production of cytokines and chemokines of pro-or anti-inflammatory potential [72-78, 80, 102] . Crosslinked FceRI takes IgE-bound antigens to the lysosomes, where the antigens are processed and loaded onto MHCII before being presented to CD4 ? T cells [61] . The functional outcome of this presentation is unclear as some studies suggest development of Th2 effector T cells [27, 86, 87] while others do not [85] Novel function of FceRI 2357 
